SBA Member, 01.10.2017
Basilea continues to make significant progress with the global roll out of Cresemba and Zevtera through further distribution and license agreements. In June the company signed an agreement with Pfizer for Cresemba in Europe, Russia, Turkey and Israel worth up to almost USD 500 mn in milestone payments and mid teen royalties on sales, followed in September by a commercialization agreement with Cardiome Pharma for Zevtera in Europe and Israel, where Basilea will supply Zevtera at a transfer price. Both agreements effectively replace Basilea’s contract hospital field force in the core European markets. US development of Zevtera, for two cross-supportive pivotal trials under SPA in skin infections and bacteremia, will start soon and largely paid for by BARDA.
Key catalysts include:
- Start of US phase III development of Zevtera (Q4 2017)
- Completion of phase I trial of BAL3833 (H1 2018)
- Phase I results oral BAL101553 (2018)
The research analyst(s) identified on the first page of this research report hereby attest that all of the views expressed in this report accurately reflect their personal views about any and all of the subject securities or issuers. In order to ensure the independence of our research analysts, and their immediate household, are expressly prohibited from owning any securities in the valuationLAB AG research universe, which belong to their sector(s). Neither the research analyst nor his/her immediate household serves as an Officer, Director or Advisory Board Member of Basilea Pharmaceutica Ltd.
Copyright 2017 VALUATIONLAB AG All rights reserved.
FELSENRAINSTRASSE 17 | 8832 WOLLERAU | SWITZERLAND | WWW.VALUATIONLAB.COM | P: +41 79 652 67 68